STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1192 by analyst upside · 2026-06-27
ZNTL
Zentalis Pharmaceuticals, Inc.
Healthcare · Market Cap $288M · P/E 0x
ANALYST PRICE TARGET
+60.9%
implied upside to consensus target
Current Price $4.04
Consensus Target $6.5
Bull Target $10.0
Bear Target $4.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
4
Sell
0
52-Week Low $1.13
52-Week High $6.95
YTD Return +194.9%
FUNDAMENTALS
Market Cap $288M
P/E Ratio (TTM) N/A
Forward P/E -2.6x
EPS (TTM) $-1.74
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.13
52-Week High $6.95
Current Price $4.04
Bear Target $4.0
Bull Target $10.0
● Now $4.04 ● Target $6.5
TRADING DATA
Avg Volume 2.1M
YTD Return +194.9%
Analyst Count 8
Consensus Buy
Upside to Target +60.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Zentalis Pharmaceuticals, Inc. (ZNTL) is currently trading at $4.04 with a Wall Street consensus price target of $6.5, implying potential upside of 60.9% over the next 12 months. 8 analysts currently cover ZNTL, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $10.0, while the most cautious has a target of $4.0.

ZNTL operates in the Healthcare sector with a market capitalisation of $288M. The stock is up 194.9% year-to-date and is currently trading near the upper end of its 52-week range of $1.13 – $6.95.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ZNTL, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim — Reiterated
Buy → Buy 2026-04-10 62% win rate (8 calls)
Guggenheim reit
Buy → Buy 2026-03-27 62% win rate (8 calls)
Morgan Stanley — Reiterated
Equal-Weight → Equal-Weight 2025-11-12 Building track record
Wells Fargo — Reiterated
Equal-Weight → Equal-Weight 2025-08-07 Building track record
Wedbush reit
Neutral → Neutral 2025-05-15 Building track record
HC Wainwright & Co. reit
Buy → Buy 2025-05-15 31% win rate (48 calls)
Wedbush reit
Neutral → Neutral 2025-03-28 Building track record
HC Wainwright & Co. reit
Buy → Buy 2025-03-27 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
24
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →